Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1502313 | 0.98 | KDM4E (0.45) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3963134 | 0.84 | MKNK2 (0.47) | CAMKK2CHEK1CAMK2D | |
| 4-Nitrobenzoic Acid SCHEMBL17460232 | 0.81 | TDP1 (0.55) | ALDH1A1LDHAPOLBGAASRD5A2 | |
| SCHEMBL1759307 | 0.81 | KMO (0.53) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1501993 | 0.80 | ALDH1A1 (0.53) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1502412 | 0.80 | KMO (0.51) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20054187 | 0.80 | AKT1 (0.30) | — | |
| SCHEMBL23559714 | 0.79 | P4HTM (0.47) | KDM4EALDH1A1SMN1; SMN2TSHRHTT | |
| SCHEMBL4063789 | 0.76 | AKT1 (0.43) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2694736 | 0.76 | CA12 (0.50) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | claimed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | claimed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | claimed |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | AXIAL THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| CN-115666553-A | TLR2 modulator compounds, and pharmaceutical compositions and uses thereof | 轴向治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021242923-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-2984091-B1 | DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS | LILLY CO ELI (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-1082303-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| US-6140504-A | Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6080767-A | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999057099-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | KDM4E 4292/4885ALDH1A1 4063/4885RAB9A 4207/4885 |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | KDM4E 4292/4885ALDH1A1 4063/4885RAB9A 4207/4885 |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | TLR2, TLR3, TLR4 | KDM4E 4292/4885ALDH1A1 4063/4885RAB9A 4207/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | KDM4E 271/4885ALDH1A1 983/4885RAB9A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.